DOXEPRIME 25

Description

Introduction DOXEPRIME 25 is a prescription medication that contains Doxepin Hydrochloride 25 mg, a tricyclic antidepressant (TCA) known for its effectiveness in treating depression, anxiety disorders, and insomnia. Doxepin works by balancing neurotransmitters in the brain, primarily serotonin and norepinephrine, offering relief from mood disorders and promoting restful sleep. This tablet is widely prescribed by psychiatrists and neurologists due to its dual benefits: improving mood and providing sedative effects without the addictive potential of benzodiazepines. What is DOXEPRIME 25? DOXEPRIME 25 is a centrally acting tricyclic compound designed to manage various neuropsychiatric conditions. It is especially beneficial for patients who suffer from: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Chronic Insomnia linked to depression or stress Somatic symptoms associated with depression (like fatigue, body pain) Uses and Indications Depression: Helps correct chemical imbalances in the brain linked to mood regulation. Anxiety: Reduces nervousness, restlessness, and physical symptoms of anxiety. Sleep Disorders: Provides sedative action beneficial for patients with difficulty falling or staying asleep. Psychosomatic Conditions: Offers relief from symptoms such as headaches, irritable bowel, and muscle tension. Mechanism of Action Doxepin inhibits the reuptake of serotonin and norepinephrine in the brain, enhancing their availability in synaptic clefts. It also blocks histamine (H1) receptors, which accounts for its sedative properties, making it useful for insomnia. Dosage and Administration Recommended dose: 25 mg once daily or as prescribed by the physician For insomnia, it's generally taken 30 minutes before bedtime Can be taken with or without food Dosage adjustments may be needed in elderly or hepatic-impaired patients Side Effects Common side effects include: Drowsiness Dry mouth Constipation Dizziness Weight gain Blurred vision Rare but serious side effects: Urinary retention Cardiac arrhythmias Suicidal thoughts (in adolescents and young adults) Precautions Avoid alcohol and CNS depressants Use caution in elderly or debilitated patients Not recommended in patients with glaucoma or urinary retention Discontinue gradually to avoid withdrawal symptoms Drug Interactions Inform your doctor if you are taking: MAO inhibitors (contraindicated) CNS depressants (increased sedation) Anticholinergic agents SSRIs or other antidepressants (risk of serotonin syndrome) Antihypertensives and antiarrhythmics Why Choose Steris Healthcare Pvt Ltd for DOXEPRIME 25? Steris Healthcare Pvt Ltd is committed to developing evidence-based, high-quality pharmaceuticals with a focus on mental health. Our manufacturing processes are WHO-GMP certified, ensuring consistent quality, safety, and efficacy in every tablet. DOXEPRIME 25 is a result of years of clinical research and pharmaceutical excellence, trusted by doctors and mental health specialists across India. Frequently Asked Questions (FAQs) Q1. Is Doxepin addictive?No, unlike benzodiazepines, Doxepin does not lead to dependence when taken as prescribed. Q2. Can DOXEPRIME 25 be used long-term?Yes, under physician supervision, it is safe for chronic use in depression and anxiety management. Q3. How long does it take to show effect?Mood improvement may be noticed within 2–3 weeks; sleep improvement may occur within days. Q4. Is it suitable for elderly patients?Yes, but usually at lower doses to avoid side effects like dizziness or confusion. Q5. What should I do if I miss a dose?Take it as soon as you remember, but skip if it’s almost time for your next dose. Do not double-dose. Conclusion DOXEPRIME 25 is a powerful, reliable treatment option for individuals struggling with depression, anxiety, or chronic insomnia. With its dual-action profile and sedative benefit, it offers holistic neuropsychiatric care. Backed by Steris Healthcare Pvt Ltd, this formulation guarantees both therapeutic value and uncompromised quality for long-term mental wellness.